Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Use as a precursor  




2 Legality  




3 See also  




4 References  













MDMB-5Br-INACA







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

MDMB-5Br-INACA
Legal status
Legal status
Identifiers

  • methyl (2S)-2-[(5-bromo-1H-indazole-3-carbonyl)amino]-3,3-dimethylbutanoate

Chemical and physical data
FormulaC15H18BrN3O3
Molar mass368.231 g·mol−1
3D model (JSmol)

  • O=C(OC)[C@@H](NC(=O)c1n[NH]c2ccc(Br)cc21)C(C)(C)C

  • InChI=1S/C15H18BrN3O3/c1-15(2,3)12(14(21)22-4)17-13(20)11-9-7-8(16)5-6-10(9)18-19-11/h5-7,12H,1-4H3,(H,17,20)(H,18,19)/t12-/m1/s1

  • Key:QGEVEXPJOKFMAN-GFCCVEGCSA-N

MDMB-5Br-INACA is an indazole-3-carboxamide derivative which has been sold as a designer drug.[2] Surprisingly it appears to produce psychoactive activity despite the lack of a "tail" group at the indazole 1-position, but is of relatively low potency and has been encountered being misrepresented as other illicit drugs such as MDMA.[3][4]

Use as a precursor

[edit]

MDMB-5Br-INACA is believed to be used as a precursor in the synthesis of synthetic cannabinoids. It has been sold online as "half finished" synthetic cannabinoids, sometimes as a "chemistry kit" with other compounds required to complete the reaction. This reaction would complete MDMB-5Br-INACA by giving it a "tail" group required for high cannabinoid activity. Other precursors lacking a tail chain have also been marketed such as (ADB-5-Br-INACA),[5] (CH-IATA), (ADB-IACA), and (ADB-5’Br-EZO-CA). This may be due to increasing legality changes worldwide on synthetic cannabinoids.[6][7]

Legality

[edit]

In the United States, MDMB-5Br-INACA is unscheduled at the federal level as of May 22nd, 2023.

North Dakota has placed MDMB-5Br-INACA (along with ADB-5'Br-BINACA, ADB-5'Br-BUTINACA and ADB-5-Br-INACA) into Schedule I on 04/27/2023.[8]

See also

[edit]

References

[edit]
  1. ^ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
  • ^ "CFSRE Analysis Report" (PDF). Indianapolis-Marion County Forensic Services Agency. 17 May 2022.
  • ^ "Drug testers warn of new synthetic cannabinoid being sold as MDMA". New Zealand Herald. 5 August 2022.
  • ^ Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, et al. (October 2023). "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. doi:10.1002/dta.3592. PMID 37903509. S2CID 264671035.
  • ^ Choi H, Kim S, Jang H, Kim HJ, Choe S (September 2022). "Identification of a novel bromoindazole synthetic cannabinoid analogue in seized e-cigarette liquid: ADB-BRINACA". Forensic Science International. 338: 111385. doi:10.1016/j.forsciint.2022.111385. PMID 35863161.
  • ^ "Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms" (PDF). Advisory Council on the Misuse of Drugs. 2022.
  • ^ Andrews R, Jorge R, Christie R, Gallegos A (April 2023). "From JWH-018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day". Drug Testing and Analysis. 15 (4): 378–387. doi:10.1002/dta.3422. PMID 36507715.
  • ^ "AN ACT to amend and reenact sections 19-03.1-05, 19-03.1-11, and 19-03.1-13 of the North Dakota Century Code, relating to the scheduling of controlled substances; and to declare an emergency" (PDF). Sixty-eighth Legislative Assembly of North Dakota in Regular Session. 3 January 2023.
    • Stub icon

    This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=MDMB-5Br-INACA&oldid=1215032924"
    Categories: 
    ●Cannabinoids
     ●Designer drugs
     ●Indazolecarboxamides
     ●Bromoarenes
     ●Methyl esters
     ●Cannabinoid stubs
     Hidden categories: 
    ●CS1 Brazilian Portuguese-language sources (pt-br)
     ●Articles with short description
     ●Short description matches Wikidata
     ●Chemical articles without CAS registry number
     ●Articles without EBI source
     ●Chemical pages without ChemSpiderID
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without UNII source
     ●Drugs missing an ATC code
     ●Articles containing unverified chemical infoboxes
     ●All stub articles
      


    ●This page was last edited on 22 March 2024, at 18:51 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki